Fig. 2: Ulotaront does not affect the mIPSC in striatal MSNs. | Neuropsychopharmacology

Fig. 2: Ulotaront does not affect the mIPSC in striatal MSNs.

From: TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner

Fig. 2

A Schematics of recording strategy (top) and experimental time course (bottom). mIPSCs were recorded in D1-expressing (tdTom + ) and D1-non-expressing (tdTom-) MSNs using whole-cell V-clamp configuration and with TTX, D-AP5 and NBQX added into the aCSF. Frequency and amplitude of mIPSC were analyzed during pre-drug baseline condition and for the last 5 min of treatment with 10 μM ulotaront or vehicle. B Representative traces of mIPSC activity before (left) and during ulotaront application (right), for both D1-expressing (top) and D1-non-expressing (bottom) MSNs. C−F mIPSC in D1-expressing MSNs. Average frequency (C) and amplitude (E) of mIPSC during baseline and upon bath application of 10 μM ulotaront or vehicle. Effect of treatment with vehicle vs ulotaront on frequency (D) and amplitude (F) of mIPSC. Data were normalized to baseline and presented as time course (left) as well as summary plot (right; each dot represents a cell, as in (C, E)). G−J Analysis on D1-non-expressing (putative D2-expressing) MSNs, corresponding to (C−F). Data are mean ± s.e.m; n = 8 -9 slices. Statistics are described in Table S1. ns, not significant.

Back to article page